(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Optimizing Cure for High-Risk Clinically Localized Prostate Cancer”, Rana McKay, MD, from Moores Cancer Center at University of California San Diego Health presented a plenary talk discussing systemic therapy strategy for patients with high-risk localized prostate cancer. She began by laying out a number of learning objectives including defining high-risk prostate cancer; reviewing novel neoadjuvant systemic therapies for used with radical prostatectomy; examining emerging adjuvant systemic therapies following radical prostatectomy; and looking at advances in systemic therapy combined with radiotherapy.